# Physical Therapy Surveillance in Children with Acute Lymphoblastic Leukemia: A Quality Improvement Initiative

**Authors:** Paula A. Ospina, Sara Fisher, Beverly A. Wilson, Lesley Pritchard, David D. Eisenstat, Cindy Fuengeling, Margaret L. McNeely

PMC · DOI: 10.3390/pediatric18020036 · 2026-03-03

## TL;DR

This study explores adding new tests to physical therapy surveillance for children with leukemia to better detect treatment-related impairments.

## Contribution

The study introduces additional functional tests to a PT surveillance program for children with ALL to better identify treatment-related deficits.

## Key findings

- 19 out of 20 children showed deficits in at least two physical function tests.
- Decreased ankle range of motion was the most prevalent deficit in standard PT tests.
- Impaired motor and sensory function was the most common deficit in additional tests.

## Abstract

Background/Objectives: Children with acute lymphoblastic leukemia (ALL) often experience treatment-related side effects. Physical therapy (PT) surveillance programs are helpful in identifying impairments; however, they do not typically incorporate assessments for peripheral neuropathy, motor proficiency, and foot drop. Our aim is to explore the feasibility of conducting additional functional tests to an existing surveillance program to improve the identification of impairments and characterize the prevalence of treatment-related deficits in children with ALL. Methods: A prospective, longitudinal descriptive study, embedded into a quality improvement initiative, was conducted. The surveillance program included standard assessments for ankle range of motion, activity level, balance, functional capacity, pain, gait, and kneeling to standing. Additional tests included motor and sensory function, foot posture, motor performance, quality of life, feasibility (recruitment and completion rates), service provision, and self-reported symptoms. Data were collected over 3 months. Results: Twenty children completed the study and 19 completed all assessments. Nineteen children presented deficits in at least two physical function tests. The most prevalent deficit identified from standard PT tests included decreased ankle range of motion (n = 19; 95%), and the most common deficit seen in the additional tests was impaired motor and sensory function (n = 14/19; 74%). Pain was the most common self-reported symptom in the checklist and the second worst subscale score in the pain dimension of the quality of life questionnaire (p < 0.001). Conclusions: Several treatment-related deficits were identified in children with ALL. Further research is warranted to explore the use of a standardized symptom checklist for the timely identification of functional limitations and impairments.

## Linked entities

- **Diseases:** acute lymphoblastic leukemia (MONDO:0004967)

## Full-text entities

- **Diseases:** injury to (MESH:D014947), neurodevelopmental or genetic disorder (MESH:D002658), balance impairments (MESH:D060825), nausea (MESH:D009325), abnormal bleeding (MESH:D006470), sensory deficit (MESH:D012678), neuromuscular impairments (MESH:D009468), myopathy (MESH:D009135), deficits in gait efficiency and energy expenditure (MESH:D020233), physical (MESH:D059445), Cancer (MESH:D009369), autism (MESH:D001321), long-term disability (MESH:D000088562), CIPN (MESH:D010523), joint and/or muscle aches (MESH:D063806), mutism (MESH:D009155), seizure disorder (MESH:D004827), bruising (MESH:D003288), neurotoxic (MESH:D020258), fatigue (MESH:D005221), impaired motor and sensory function (MESH:D003072), PROM (MESH:D005322), chronic pain (MESH:D059350), toxicities (MESH:D064420), fever (MESH:D005334), Deficits (MESH:D009461), muscle weakness (MESH:D018908), deficits in fine and gross motor skills (MESH:D019957), Pain (MESH:D010146), rash (MESH:D005076), functional deficits (MESH:D001289), Decreased ankle ROM (MESH:D012021), impaired gait (MESH:D020234), Down syndrome (MESH:D004314), B-cell ALL (MESH:D015456), oncology (MESH:D000072716), functional limitations (MESH:D045745), foot drop (MESH:D020427), headache (MESH:D006261), frailty (MESH:D000073496), ALL (MESH:D054198), anxiety (MESH:D001007), numbness (MESH:D006987), motor impairment (MESH:D000068079), PT (MESH:D016609), Neuropathy (MESH:D009422), ankle ROM deficits (MESH:D064386)
- **Chemicals:** methotrexate (MESH:D008727), vincristine (MESH:D014750), dexamethasone (MESH:D003907)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13010702/full.md

---
Source: https://tomesphere.com/paper/PMC13010702